Darktrace acquires Cybersprint for €47.5m

1

Darktrace has acquired attack surface management company Cybersprint for €47.5 million.

The share price for Darktrace gained 3% to trade at 355p in Wednesday afternoon trade. Darktrace had traded as high as 361p in earlier in the session.

The acquisition comes as an addition to Darktrace’s new ‘Prevent’ product suite, which is underpinned by Attack Path Modelling.

The company said that Cybersprint will contribute to Darkspace’s ‘Continuous Cyber AI Loop’ development and will complement its self-leaning technology and inside-out view.

The transaction is set to be paid approximately 75% in cash and 25% in equity, which values the transaction at approximately 12.5 times Cybersprint’s annual recurring revenue (ARR).

“We are very excited to welcome the Cybersprint team to Darktrace,” said Poppy Gustafsson, CEO at Darktrace.

“Bringing inside-out and outside-in visibility together is critical and having access to the robust, rich, real-time external dataset combined with Darktrace’s Self-Learning AI means that customers get a holistic view of prioritised cyber risks to harden the parts of their organisation that are most vulnerable.”

“With this acquisition, we are able to leverage Cybersprint’s seven years of R&D to accelerate our Prevent product family, ultimately making it much harder for cyber-attackers to carry out successful missions.”

Pieter Jansen, CEO at Cybersprint added: “I’m very excited about this fantastic step in the journey of Cybersprint.”

“We are looking forward to joining Darktrace and working together to accelerate state-of-the-art innovations to make organisations more cyber secure.”

The acquisition is scheduled for a completion date of 1 March 2022.

Genedrive provides update on Point of Care Covid Test

0

Genedrive have made headway in rapid point of care molecular tests for Covid-19.

Genedrive shares were trading up 20.7% at 17.5p after their update on Wednesday.

On Wednesday, Genedrive provided an update which stated that the near patient molecular diagnostics company has entered distribution agreements for their rapid point of care molecular test for Covid-19.

Genedrive COV19-ID kit is a rapid molecular diagnostic testing kit. Positive results are delivered in 7 minutes and negative results are delivered in 17 minutes by the Genedrive COV19-ID kit. The results are extracted by Reverse-Transcription Loop Mediated Isothermal Amplification (RT-LAMP) and a proprietary buffer formulation.

The test is performed by administrating a mid-turbinate nasal swab, the assay targets the ORF1ab and N genes of the SARS-CoV-2 genome, adding robustness against emerging SARS-CoV-2 variants.

The product was CE marked on 8th December, 2021 enabling distribution in Spain, Portugal, Oman and the United Arab Emirates. Opportunities in the EU are currently under assessment. The main market for distribution of the Genedrive COV19-ID kit are including pharmacies, sports and private workplace.

Genedrive say the distribution agreements will provide the opportunity to access to the longer-term market potential in each country.

End-user product evaluation is underway in the UK in order to access certain occupational health markets.

CTDA approval is pending in the UK, therefore, commercial distribution is at a halt. The UK government is assessing the statutory requirements for COVID testing and opportunities for Genedrive depend on it.

“Progress since CE marking is as expected in terms of timeline and a focus on specific use cases. We are pleased with the distributor agreements we have contracted to date and expect to expand to additional countries in due course. While UK government policy has changed, opportunities are continuing in other markets that are taking a different approach with regards to testing,” said David Budd, CEO of Genedrive.

Cohort secures torpedo-launcher contract

0

Cohort plc company SEA has secured a contract with Hyundai Heavy Industries (HHI) to supply its Torpedo Launcher System (TLS) to two of the Philippine Navy’s new corvettes.

Cohort’s share price rose to 474.80p in early morning trade, before the rally faded and shares fell back to just 1% up at 455.52p.

The contract is worth several million pounds and is scheduled to see the first TLS delivered in 2023, with the second estimated for delivery in 2025.

The TLS is reportedly a close-range and rapid-react system which is equipped to fire a selection of NATO-compatible standard lightweight torpedoes.

The system is capable of launching the US Mk44, Mk46 and Mk54 torpedoes, UK Sting Ray, Italian A244S, French MU90 and the Korean Blue Shark.

The contract comes as part of the Revised Armed Forces of the Philippines Modernization Program (RAFPMP), and follows the success of SEA’s TLS onboard the Philippine Navy’s frigates.

“The inherent flexibility of our TLS will provide the Philippine Navies with a capability that helps future-proof the corvettes against new weapon developments and obsolescence, whilst also ensuring commonality across the fleet,” said David Hinds, Vice President Strategic Accounts at SEA.

“We look forward to working with our partners across Southeast Asia and further strengthening our relationship with HHI and the Philippine Navy.”

HHI representative Mr Kyunghyun Cho added: “This contract is part of a significant modernisation programme for the Philippine Navy.”

“Following the successful delivery of SEA’s TLS for the Philippine Navy’s frigates, we were impressed by the performance and reliability of the system and are pleased to be collaborating with SEA to deliver the same superior capability to the Navy’s corvettes.”

Mosman Oil & Gas completes East Texas gas network

0

Mosman Oil and Gas finished a gas network in East Texas, connecting several leases in the area and enabling sales of gas from the Winter-2 project.

Mosman Oil and Gas share price has leaped 25.9% to 0.12p on the news of their project completion to supply gas in East Texas.

The Mosman Oil and Gas strategy focuses on exploration of existing permits and acquisition of new permits in politically stable companies. The Group works to find opportunities which will optimise operating cash flows along with positive developmental shifts.

In the new development, sale of gas is going to be supplied by Winter-2 well and Stanley-4 well. The gas network connects multiple leases, out of which one is Arcadia Operating LLC. Arcadia Operating LLC is jointly owned by Arcadia and Mosman subsidiary, Nadsoilco.

The well production flow rate will be announced after testing the system for a few days.

“Mosman is pleased to complete the construction of the gas network to further build on our production profile. With the gas network in place, it enables gas production from Winters-2 and Stanley-4, and other wells in the area. I am pleased to see increasing production volumes and cashflow, especially while gas price is strong,” said John W Barr, Chairman.

Mosman is on its way to maintaining their growth by furthering their exploration in helium and hydrogen potential in Australia and have recently released a production report that 17,344 boe, an increase of 43% compared to the six months to June 2021 of 12,143 boe.

Eve Sleep shares fly on retail partnership with DFS

Eve Sleep has secured a retail partnership with DFS which saw the company’s share price nearly doubled on Wednesday, sending Eve Sleep straight to the top of the FTSE AIM All-Share Index on the day.

Eve Sleep shares were trading 88% higher at 3.3p following the news on Wednesday.

DFS is reportedly set to stock Eve Sleep’s Original and Premium Hybrid model mattresses on its website first, alongside a selection of Eve Sleep bedframes.

The partnership has also committed to a later wider rollout to DFS national showrooms, with both parties having confirmed plans to extend the ranges at a later date.

The partnership is scheduled to go live on the DFS website on March 3 2022.

“We are delighted to be partnering with eve to add their best-in-class mattresses to our range, to support awareness of our bedroom furniture products; deliver even greater choice for our customers; and provide the opportunity for customers to conveniently add an eve mattress to their DFS furniture order,” said DFS head of home John Rastall.

Eve Sleep CEO Cheryl Calverley added: “We’re incredibly proud to announce this partnership with the UK’s foremost furniture retailer, which recognises the strength of the eve sleep product range and brand.”

“This is a very exciting partnership for eve as DFS seek to extend their ‘comfort’ positioning beyond the living room and bring eve’s award winning mattresses to a wider audience.”

OKYO Pharma: New Patent for Ocular Neuropathic Pain

0

OKYO Pharma has been approved for a new patent titled, “Methods and Systems for Designing and/or Characterizing Soluble Lipidated Ligand Agents,” by the USPTO.

OKYO Pharma is in the business of finding solutions for ocular pains and diseases. With the use of G-Protein Coupled Receptor (GPCR) Platform technology, OKYO Pharma plans to produce therapies for inflammatory eye diseases and ocular pain management.

Following the patent update, the OKYO Pharma share price jumped 13.3% to trade at 8.5p.

With the patent issued today, OKYO is in position to develop the OK-101 drug. The OK-101 drug is in the pre-clinical phase currently. OK-101 is the lead compound for OKYO Pharma in the battle against dry eye disease (DED). OKYO and the FDA had an amicable meeting regarding pre-IND (Investigational New Drug), where non-clinical and clinical development plans were discussed. And now OKYO is enroute to filing the IND for OK-101 by Q3/4 of 2022.

“The pain reducing feature of OK-101 offers the opportunity that our drug can potentially treat neuropathic corneal pain, a severe, chronic and debilitating disease for which there are no approved commercial treatments currently available” stated Raj Patil, PhD, Chief Scientific Officer of OKYO.

Ocular Diseases

The Pharma company is focused on developing drugs for:

  • Dry Eye Disease – inflammation in the eyes due to lack of lubrication and moisture on the surface of the eye. More than 35% of people of 50 suffer from DED.
  • Non-infectious Anterior Uveitis – inflammation in the iris which is the third leading cause of blindness
  • Allergenic Conjunctivitis – allergic reaction which leads to inflamed conjunctiva. Upto 40% of the population of the planet suffer from pink eye.
  • Ocular Pain – pain in the eyes due to trauma, infection, post-surgical, dry eye syndrome, uveitis, corneal abrasions or ulcers. Approximately 5 million people suffer from ocular pain every year.

Pipeline

There are only two drugs under development by OKYO Pharma:

  • OK-101 – Used to aid DED, Uveitis & Allergic Conjunctivitis
    • Development is at pre-clinical
  • OK-201 – Used to help ocular pain
    • Still under lead optimisation

Barclays, Rio Tinto, and Rising Rates with Alan Green

The UK Investor Magazine Podcast is joined by Alan Green as we explore UK equites and key market themes. 

We start by questioning the current narrative and if markets are underestimating the risk of rising rates as investor attention shifts to Eastern Europe. 

Rio Tino is one of two FTSE 100 companies reporting record profits on Wednesday as rising commodity prices saw earnings soar and gave the board confidence to hike the dividend, making Rio Tinto one of the FTSE 100’s top dividend payers.

Barclays also reported record profits as the banking group enjoyed strong investment banking activity and the reversal of impairment charges. Income investors will be pleased Barclays is also raising their dividend. 

Mosman Oil and Gas recently released a dramatic increase in production figures and has updated the market of developments at exploration projects concerned with Helium resources. 

We cover the latest developments at Blencowe Resources which is working to supply the EV market.   

Barclays shares rise on record profit

1

Barclays shares were trading up 1.8% at 193.5p in early trade on Wednesday after profits jumped on strong investment banking activity and impairment reversals.

Barclays has reported revenue at £21.9b with a 1% increase from last year (£21.7b), as a result of Barclay’s diversified income stream.

The Group delivered a record annual profit before tax of £8.4b which is 174% higher than 2020 results (£3.06b). The CET1 ratio remains unchanged at 15.1% whilst the bank’s RoTE was 13.4%.

With the economy recovering, UK and US consumers exhibited positive trends in consumer spending. UK mortgage lending and deposits increased.

An improved macroeconomic outlook are set to have a positive impact on unsecured lending balances in the coming quarters and Barclays said they see impairment charges returning to below pre-covid levels. Barclays operating profit was helped higher by the net reversal of £653m provisions made during the pandemic.

Barclay’s Corporate and Investment Banking division was gain a strong performer seeing Net Profit for 2021 increase to £5.8bn.

“Barclays is the sixth largest global investment bank – a fact sometimes overlooked thanks to its position as a UK high street staple. This position means Barclays is far, far less reliant on traditional interest income, and instead generates most of its income from fees, commission and trading,” said Sophie Lund-Yates, Lead Equity Analyst at Hargreaves Lansdown.

“In the short term that means rising interest rates have less of an immediate benefit than for the likes of Lloyds, which has more traditional income streams. However, looking to the long-term and the expansion of public and private markets, this diversified business model is an area of interest.”

Having being forced to scrap dividend payout during the pandemic, Barclays has began to gradually increase shareholder payouts and is set to pay 6.0p in the 2021 full year, a sharp increase from the 1p paid in 2020.

With results like these, it is safe to say that C. S. Venkatakrishnan, Group Chief Executive, is pleased.

“Barclays demonstrated a clear and sustainable path to growth over the course of 2021, delivering double-digit RoTE across our operating businesses, and returning £2.5 billion of excess capital. Our strategic priorities will continue to develop the diversified business model that we have established, investing in advanced technology capabilities in our consumer businesses, delivering sustainable growth across our global Corporate and Investment Bank, and reinforcing our commitment to aiding the transition to a low-carbon economy,” stated C. S. Venkatakrishnan.

Going forward, the bank, plans to adapt and benefit from the changes coming in the financial services sector. Barclays plans to do so by improving customer service with advances in digital services.

Barclays foresees global growth in private and public capital markets, to which they believe they will be able to reap the benefits of by continuing to diversify their income streams and carry on innovating. Barlcays also plans on taking opportunities during the low-carbon trend, by helping the business and their consumers transition to a more sustainable position.

Rio Tinto rewards investors with record dividend as earnings soar

0

Rio Tinto has announced record financial results in its full-year financial report for 2021.

The Anglo-Australian mining company reported an 88% free cash flow increase to $17.7bn, following a 42% leap in revenues.

Rio Tinto rewarded investors with a record $16.8 billion in full-year dividends, equating to 1,040 US cents per share, alongside a special dividend of 247 US cents per share.

The dividends amounted to a 79% payout for shareholders in the company.

The company cited global economic recovery post-Covid-19 for its record financial results, consequently helping it retain approximately 80% of the benefit from rising prices.

Rio Tinto cited the Platts index strength with a 62% in iron fines, alongside the Higher London Metal Exchange (LME) prices for acting as a driving factor behind the strong price boost for its copper and aluminium profitability.

“These results are all about commodity prices and the cash flow that comes from low production costs,” said Steve Clayton, Fund Manager at HL Select.

“Iron Ore revenues drive the majority of Rio’s revenues and with ore prices strong and Rio’s operating costs amongst the lowest in the industry, cash generation was always going to be strong in 2021.”

Rio Tinto Portfolio

The metals producer further highlighted recent developments in its portfolio, including the opening of underground gold and copper mining operations in Mongolia after the Mongolian government approved the Oyu Tolgoi agreement.

The deal has allowed the company to start operations in the country, with first sightings of sustainable production estimated for the first half of 2023.

The company also confirmed its agreement to acquire the Rincon lithium project based in Argentina.

“Our people have continued to safely run our world-class assets and are working hard to improve our operational performance, despite challenging operating conditions from prolonged COVID-19 disruptions,” said Rio Tinto Chief Executive Jakob Stausholm.

“The recovery of the global economy, driven by industrial production, resulted in significant price strength for our major commodities, which we were able to capture, achieving record financial results with free cash flow of $17.7 billion and underlying earnings of $21.4 billion, after taxes and government royalties of $13.0 billion.”

Aston Martin posts “significant progress”

1

Aston Martin has posted an 82% increase in wholesales.

Revenues at the group increased to £1.1bn thanks to strong customer demand.

“The operating environment remained challenging throughout 2021,” said Tobias Moers, Aston Martin’s CEO.

“Despite this, we grew our core business to plan, with a demand-led delivery of our volume targets and enhanced core profitability. We achieved strong pricing and closed the year with dealer stock at optimum levels.”

” We also started delivery of the once-in-a-generation Aston Martin Valkyrie hypercars. This was achieved despite the technical ambition of the product, supply chain constraints and with no compromise on quality, resulting in fewer cars than originally planned shipping in 2021.”

“Beyond 2022 we are confident in the medium and long-term potential for the business with our exciting product plans and a defined path to electrification”, he added.